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Abstract 30	  
Canine hemangiosarcoma is a neoplasm of vascular endothelial origin that has an 31	  
aggressive biological behavior, with less than 10% of dogs alive at 12 months post 32	  
diagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-33	  
based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine 34	  
(ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at 35	  
determining safety and assessing whether this regimen prolongs survival and time to 36	  
metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up 18 37	  
were treated with AC and 9 with ADTIC. Median TTM and survival time were longer 38	  
for dogs treated with ADTIC compared to those receiving AC (>550 vs 112 days, 39	  
p=0.021 and >550 vs 142 days, p=0.011, respectively). Both protocols were well 40	  
tolerated, with no need for dose reduction or increased interval between treatments. A 41	  
protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with 42	  
hemangiosarcoma and prolongs TTM and survival time. 43	  
 44	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Introduction 49	  
Hemangiosarcoma (HSA) is a common tumor in dogs, arising in three different forms: 50	  
dermal, subcutaneous/muscular and visceral, the latter mainly involving spleen, right 51	  
atrium or auricle, and liver.1-3 With the exception of the dermal form, which may 52	  
behave in a less aggressive fashion, subcutaneous/intramuscular and visceral HSA is a 53	  
highly malignant cancer, spreading rapidly to lungs, liver, peritoneum and central 54	  
nervous system.4,5 Unfortunately, visceral HSA has a silent evolution for a quite long 55	  
time, and is accompanied by non specific clinical signs. As a consequence, when 56	  
detected, it is usually in an advanced or metastatic stage, therefore precluding cure.1,2 57	  
The mainstay of treatment consists of surgery followed by adjuvant intravenous 58	  
chemotherapy.6,7 Doxorubicin-based chemotherapy protocols have been administered to 59	  
dogs with HSA, including doxorubicin as single agent,6 or combined with ifosfamide,8 60	  
vincristine and cyclophosphamide,7,9-11 and epirubicin as single agent.12 Although a 61	  
three weekly regimen is the commonest schedule administration of doxorubicin, one 62	  
study attempting to increase dose intensity by more frequent administrations showed 63	  
such strategy to be well tolerated, although without improved survival time.13 A 64	  
metronomic strategy has been also proposed as an alternative treatment, yielding 65	  
comparable results to conventional dose-intense chemotherapy.14 66	  
More recently, a combined chemotherapy protocol consisting of doxorubicin, 67	  
dacarbazine, and vincristine (DAV) was evaluated in metastatic canine HSA.15 Results 68	  
suggested that the DAV combination offers clinical response and might prolong 69	  
survival in dogs with advanced clinical stage HSA. These patients typically have a 70	  
grave prognosis and treatment options different from hospice or euthanasia are usually 71	  
discouraged. Thus, the results obtained in the aforementioned study raised interest 72	  
towards the use of dacarbazine for the treatment of canine HSA. However, significant 73	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haematological and/or gastrointestinal toxicities were observed with DAV, leading to 74	  
discontinuation of treatment in almost 20% of the patients.15  75	  
Dacarbazine is a nonclassical alkylating, phase-aspecific agent, which methylates the 76	  
deoxyribonucleic acid (DNA) at the O6 methyl group of guanine.16 Dacarbazine has 77	  
been previously used in dogs for the treatment of relapsed or resistant lymphomas, high-78	  
grade sarcomas, and malignant melanomas, either as single agent or combined with 79	  
lomustine or doxorubicin.17-22  80	  
Results of in vitro and in vivo studies suggest that dacarbazine acts synergistically with 81	  
anthracyclines and has a moderate effect in the treatment of high-grade sarcomas in 82	  
humans, leading to the need of further investigations of this compound in the treatment 83	  
of canine HSA.23-25 84	  
As single agent, a dose up to 1000 mg/m2 IV over 6-8 hours and 1500 mg/m2 as a single 85	  
bolus may be administered to dogs and humans, respectively, every 3 to 4 weeks;16,19,26-86	  
27 however these regimens have been largely replaced in human practice by a daily dose 87	  
of 250mg/m2 administered over 5 consecutive days, leading to reduced gastrointestinal 88	  
toxicity beside similar antitumour activity.16,28 89	  
In the current study, we prospectively compared adjuvant chemotherapy with 90	  
doxorubicin and daily dacarbazine boluses to a traditional doxorubicin and 91	  
cyclophosphamide treatment, aiming at determine safety and assessing whether this 92	  
regimen prolongs survival time and time to metastasis (TTM) in HSA dogs that 93	  
underwent surgical intervention.  94	  
 95	  
 96	  
Materials and methods 97	  
 98	  
Patient eligibility 99	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Client-owned dogs with a surgically removed, histologically confirmed HSA, arising 100	  
from any abdominal organ or subcutis, were prospectively recruited. Post-surgical 101	  
investigations included physical examination, haematology, serum biochemistry, 102	  
abdominal ultrasound and at least two lateral views thoracic radiographs.  103	  
Dogs were considered to be at high-risk for developing doxorubicin-related 104	  
cardiotoxicity if systolic fractional shortening determined by echocardiography was 105	  
<25%. Dogs with such cardiac function were not enrolled in the study. Dogs with life-106	  
limiting diseases different than HSA and those with dermal HSA were also excluded. 107	  
Dogs were staged according to the World Health Organization (WHO) staging system 108	  
for domestic animals.29  109	  
Dogs referred to the institution of one author (DS) were included in Group 1, whereas 110	  
dogs referred to the institutions of two different authors (LM, RF) were included in 111	  
Group 2.  112	  
 113	  
Treatment protocol 114	  
The objective was to initiate chemotherapy within 7-10 days after surgical intervention. 115	  
Dogs included in Group 1 were treated with adjuvant doxorubicin (Doxorubicina, 116	  
Ebewe Italia s.r.l., Roma, Italy) and cyclophosphamide (Endoxan®, Baxter s.r.l., Lurago 117	  
d'Erba, Como, Italy) (AC), whereas dogs included in Group 2 received doxorubicin and 118	  
dacarbazine (Deticene®, Aventis Pharma S.p.A, Milano, Italy) (ADTIC). 119	  
ADTIC had higher costs compared to AC, and as the study was not supported by a 120	  
grant, groups could not be randomized. All owners electing ADTIC were asked to sign a 121	  
written informed consent prior to enrolment. 122	  
In either treatment groups, doxorubicin was administered intravenously (IV) at the dose 123	  
of 30 mg/m2 every 3 weeks for 4 cycles.  124	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In Group 1, cyclophosphamide was administered orally at 75 mg/m2 for 4 consecutive 125	  
days, starting on the day of every doxorubicin administration. 126	  
In Group 2, dacarbazine was administered as an IV bolus at the dose of 200 mg/m2 127	  
(without exceeding 250 mg total daily) once daily for 5 days, starting on the day of 128	  
every doxorubicin administration.  129	  
Fractional and summation dose intensities (SDI) for the two protocols are listed in Table 130	  
1.30 131	  
In either group, standard antiemetic therapy consisted in maropitant (Cerenia®, Pfizer, 132	  
Latina, Italy) administered orally at the dose of 2 mg/kg q24h for 3 consecutive days 133	  
starting on the first day of chemotherapy. Clavulanate-potentiated amoxicillin 134	  
(Synulox®, Pfizer, Latina, Italy) was prophylactically administered orally at 12.5-20 135	  
mg/kg q12h until the time of the expected neutropenic nadir, and as indicated thereafter. 136	  
Antibiotic dosage depended on clinician’s preference.  137	  
A repeated clinical staging work-up consisting of thoracic radiographs and abdominal 138	  
ultrasound was performed after 2 cycles of chemotherapy. If no local recurrence and/or 139	  
metastatic disease were observed, the same chemotherapy protocol was continued for 140	  
two additional cycles. In case of disease progression, a rescue protocol was offered. 141	  
 142	  
Assessment of toxicity 143	  
Toxicity resulting from chemotherapy was assessed in Group 1 based on the dog’s 144	  
history, physical examination and complete blood count (CBC) performed 7-10 days 145	  
after doxorubicin and before the beginning of each cycle, as stated by the Veterinary 146	  
Co-operative Oncology Group.31 In Group 2, CBC was checked on day 1, 4, 5, 10 of 147	  
each chemotherapy cycle. Day 1 was considered as the day of doxorubicin 148	  
administration. 149	  
 150	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 151	  
Statistical analysis 152	  
Follow-up and survival times were calculated from the date of diagnosis to the date of 153	  
last visit or death. For both groups, survival time and TTM (beyond regional lymph 154	  
nodes), were explored with the Kaplan-Meier product limit method followed by log-155	  
rank test. In either group, timing was considered from surgical excision. In the survival 156	  
analysis, dogs were censored if they were alive at the time of data accrual closure or 157	  
died of no tumour-related causes, whereas for TTM dogs were censored if, by the last 158	  
examination, distant metastases had not developed.  159	  
To verify whether characteristics of the two treatment groups differed at admission, the 160	  
Mann Whitney test was used to compare age and body weight, and the Fisher’s exact 161	  
test was used to compare breed (pure- vs cross-breed), sex (male vs female), primary 162	  
location of the tumor (spleen vs other sites), clinical stage (II vs III) and surgical 163	  
margins (complete vs incomplete). The latter test was also used to compare the 164	  
frequency of bone marrow toxicity (present vs absent) that occurred during treatment 165	  
cycles. P<0.05 was considered significant. 166	  
 167	  
 168	  
Results 169	  
Between 2008 and 2014, 27 dogs met the inclusion criteria and were enrolled; 18 170	  
(66.6%) of them received adjuvant AC (Group 1), whereas the remaining 9 (33.3%) 171	  
were treated with ADTIC (Group 2). Features of the dogs are listed in Table 2. 172	  
At admission, the two treatment groups did not differ for age, body weight, breed, sex, 173	  
primary location of the tumour and stage, whereas surgical margins were more often 174	  
dirty in dogs allocated to receive ADTIC than in those allocated to receive AC [5 of 9 175	  
(55.6%) vs. 2 of 18 (11.1%), respectively; p=0.024]. 176	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 177	  
Group 1 178	  
There were 9 mixed breed dogs, 2 Boxer, 2 German shepherd, 2 Golden retrievers, 1 179	  
English setter, 1 Labrador retriever and 1 Italian cane corso. Median age was 9.5 years 180	  
(range, 6 to 13 years) and median weight was 31 kg (range, 5.2 to 46.4 Kg). There were 181	  
11 males (n=3 neutered) and 7 female dogs (n=4 spayed). HSA occurred in the spleen 182	  
as primary site in 15 dogs; 11 of them presented with hemoperitoneum because of 183	  
splenic rupture. The remaining three dogs had a renal, hepatic and a subcutaneous HSA, 184	  
respectively.   185	  
Each dog underwent surgery, consisting of splenectomy, left hepatic lobectomy, 186	  
nephrectomy or removal of the subcutaneous tumor, according to cancer location. 187	  
Histopathological evaluation revealed clean surgical margins in the hepatic and 188	  
subcutaneous HSA; surgical margins were deemed not assessable if the dog was 189	  
presenting with visceral rupture.  190	  
According to the TNM classification, 16 were considered having stage II and 2 having 191	  
stage III HSA. Both dogs with stage III disease had a splenic HSA and macroscopic 192	  
evidence of metastasis to the omentum; metastatic disease was suspected during 193	  
celiotomy and this was confirmed through histopathology. Multiple military lesions 194	  
were observed and metastasectomy could not be performed. No regional 195	  
lymphadenomegaly and/or other metastatic sites could be documented. Cases are 196	  
summarized in Table 2.    197	  
The median time from surgery to the initiation of chemotherapy was 9 days (range, 7-198	  
10). The median number of chemotherapy cycles was 4 (range, 2 to 5), with a median 199	  
cumulative dose of doxorubicin of 120 mg/m2 and a median cumulative dose of 200	  
cyclophosphamide of 1200 mg/m2. The median received SDI for this protocol 201	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corresponded to the intended SDI, as none of the dogs required dose reductions and/or 202	  
treatment delays.  203	  
 204	  
Group 2 205	  
There were 6 mixed breed dogs, 1 American Staffordshire terrier, 1 Golden retriever 206	  
and 1 Labrador retriever. Median age was 9 years (range, 8 to 14 years) and median 207	  
weight was 26.4 kg (range, 10 to 39.2 kg). There were 3 males (n=1 neutered) and 6 208	  
female dogs (n=4 spayed). HSA occurred in the spleen as primary site in 5 dogs; all of 209	  
them presented with hemoperitoneum because of splenic rupture. Two dogs had 210	  
subcutaneous HSA, one dog had a renal and one had a mesenteric HSA. According to 211	  
the TNM classification, 6 dogs had stage II (n=2 splenic, n=2 subcutaneous, n=1 renal, 212	  
n=1 mesenteric) HSA, and 3 dogs had stage III (n=3 splenic) HSA. One dog with 213	  
subcutaneous stage II HSA had lymphadenomegaly of the ipsilateral regional lymph 214	  
node; this was surgically excised and metastatic disease was confirmed on 215	  
histopathology. Two out of the 3 dogs with stage III disease had peritoneal metastases, 216	  
and 1 had liver metastases. All dogs underwent surgery, consisting of splenectomy, 217	  
nephrectomy, removal of mesenteric and subcutaneous tumour, according to cancer 218	  
location; in all cases with stage III disease, metastasectomy was not possible due to the 219	  
multiple number of metastases. Of the three subcutaneous HSA, 2 were removed with 220	  
complete margins, whereas one had incomplete margins (T2N0M0). Cases are 221	  
summarized in Table 2. 222	  
The median time from surgery to the initiation of chemotherapy was 9 days (range, 7-223	  
10). The median number of chemotherapy cycles was 4 (range, 2 to 4 cycles), with a 224	  
median cumulative dose of doxorubicin of 120 mg/m2 (range, 60 to 120 mg/m2) and a 225	  
median cumulative dose of dacarbazine of 4000 mg/m2 (range, 2000 to 4000 mg/m2). 226	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The median number of chemotherapy cycles was 4 (range, 2 to 4). The median received 227	  
SDI for this protocol corresponded to the intended SDI.  228	  
 229	  
Additional treatments 230	  
Additional treatments were permitted at the time of development of metastatic disease. 231	  
These were instituted only in three dogs. In Group 1, a dog with splenic stage II HSA 232	  
received cyclophosphamide and piroxicam in a metronomic regimen, and in Group 2 a 233	  
dog with stage II renal HSA and one with splenic stage III HSA received ifosfamide 234	  
followed by masitinib mesylate.  235	  
 236	  
Clinical outcome 237	  
Thirteen (72.2%) out of the 18 dogs in Group 1 developed metastatic disease after a 238	  
median of 89 days (range, 44 to 188 days). Metastases were found in the liver (n=7), 239	  
lungs (n=3), peritoneum (n=2), liver and lungs (n=1). The two dogs with metastases to 240	  
the peritoneum developed haemoabdomen. One (11.1%) out of the 9 dogs included in 241	  
Group 2 developed pulmonary metastasis after 378 days. The 3 dogs already having 242	  
metastasis at presentation had disease progression documented after X, Y, and Z days. 243	  
In these dogs, metastases were found in the lungs (n=1), peritoneum (n=1), kidney and 244	  
liver (n=1). Overall, median TTM as calculated with Kaplan-Meier product limit was 245	  
significantly longer for dogs receiving ADTIC compared to those receiving AC (>550 246	  
days versus 112 days, respectively; p=0.021; Figure 1).   247	  
Sixteen (88.8%) out of the 18 dogs included in Group 1 died by the end of the study: 15 248	  
(83.3%) died as a result of HSA progression with a median survival time of 140 days 249	  
(range, 37 to 301 days), whereas one dog died after 158 days because of gastric 250	  
dilatation-volvulus with no evidence of tumor recurrence or metastasis. Two dogs with 251	  
splenic stage II HSA were still alive, 85 and 262 days after the diagnosis. 252	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Seven (77.7%) out of the 9 dogs in Group 2 died by the end of the study: 4 (44.4%) died 253	  
as a result of HSA progression with a median survival time of 106 days (range, 74 to 254	  
480 days). Of these 4 dogs, 3 had splenic stage III HSA and 1 had renal stage II HSA. 255	  
Regarding the remaining 3, 1 of them (splenic stage II HSA) died 803 days after the 256	  
diagnosis due to gastric dilatation-volvulus, one (splenic stage II HSA) died after 960 257	  
days due to advanced chronic kidney disease (IRIS stage IV), and one (mesenteric stage 258	  
II HSA) died after 1230 days due to a metastatic mast cell tumour. Two dogs with 259	  
subcutaneous stage II HSA were still alive, 572 and 1260 days after the diagnosis. 260	  
Overall, dogs receiving ADTIC had significantly longer median survival than those 261	  
receiving AC (>550 days versus 142 days, respectively; p=0.011; Figure 2). 262	  
In Group 1 none of the dogs was alive at one year after diagnosis whereas in Group 2 263	  
the 1 and 1.5 years survival rate was 66.8% and 55.8%, respectively.  264	  
 265	  
Safety 266	  
All dogs were evaluated for toxicity. In Group 1, a total of 77 CBCs were evaluated; 267	  
neutropenia was the only type of bone marrow toxicity, occurring in 6 (33.3%) dogs. 268	  
Grade 1 neutropenia occurred in 5 dogs, whereas 1 dog developed a grade 3 non-febrile 269	  
neutropenia. In all dogs neutropenia developed after the first treatment and resolved 270	  
without sequel. No further hematological toxicities were recorded. 271	  
In Group 2, a total of 96 CBCs were evaluated; neutropenia was the only type of bone 272	  
marrow toxicity, occurring in 7 (77.7%) dogs. Two episodes of grade 1 neutropenia 273	  
occurred in 1 dog, 6 episodes of grade 2 neutropenia occurred in 5 dogs, 4 episodes of 274	  
grade 3 neutropenia occurred in 2 dogs, and 1 episode of grade 4 non-febrile 275	  
neutropenia occurred in one dog. Two dogs developed neutropenia after each cycle, 2 276	  
dogs after the third cycle and 2 dogs had only 1 episode of neutropenia during 277	  
treatment. Among them, 1 developed a grade 2 febrile neutropenia after the second 278	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cycle, which resolved uneventfully after symptomatic treatment. The median number of 279	  
cycles administered before developing neutropenia was 2 (range, 1 to 2 cycles) and the 280	  
median number of cycles with dogs showing neutropenia was 3 (range, 1 to 4 cycles). In 281	  
all dogs neutropenia resolved without sequel.  282	  
The frequency of neutropenia was higher in dogs that received ADTIC than in those that 283	  
received AC (7 of 9 (77.8%) versus 6 of 18 (33.3%), respectively; p=0.046). 284	  
Gastrointestinal toxicity was the second most common adverse event in both groups, 285	  
and consisted of vomiting and decreased appetite. Gastrointestinal toxicity occurred in 7 286	  
(38.8%) dogs in Group 1: 2 dogs had grade 1 side effects (one concurrently had grade 1 287	  
neutropenia), 4 dogs had grade 2 (2 concurrently had grade 1 neutropenia) and 1 dog 288	  
had grade 3 toxicity. In every case, a single episode of gastrointestinal toxicity was 289	  
recorded. In Group 2, 3 (33.3%) dogs developed gastrointestinal toxicity; 2 dogs had 290	  
grade 1 (1 concurrently had grade 1 neutropenia) and 1 had grade 2 toxicity. The 291	  
frequency of gastrointestinal side effects did not differ between groups (p=1.000). 292	  
Alopecia occurred in one dog in Group 1 at the end of the fourth cycle. No other 293	  
toxicities were recorded. 294	  
 295	  
 296	  
Discussion 297	  
The treatment of HSA continues to be extremely challenging in veterinary oncology and 298	  
prognosis for dogs with HSA is poor as a result of aggressive disease, leading to 299	  
invasion of nearby organs and vessels, early metastasis and limited treatment options 300	  
providing durable disease control. Surgery is designed to remove all macroscopic 301	  
tumors and prevent further risk of acute hemorrhage, but is considered purely palliative. 302	  
The addition of chemotherapy in an effort to treat microscopic disease has been 303	  
documented to provide a modest improvement in outcome, with reported median 304	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survival times in the range of 6-8 months and less than 10% of dogs being alive at 12 305	  
months.1,2  306	  
In this study, we used a combination of doxorubicin and dacarbazine as adjuvant 307	  
chemotherapy to determine the safety and efficacy of this treatment in biologically 308	  
aggressive canine HSA.  309	  
This study showed that the ADTIC combination is feasible and can be safely 310	  
administered every 21 days in dogs with HSA, thereby allowing compliance with 311	  
projected drug doses and scheduled intervals between cycles. All dogs were treated on 312	  
an outpatient basis, stressing the feasibility of the presently described ADTIC regimen. 313	  
Side effects were reversible and manageable, with neutropenia being the primary 314	  
toxicity. One dog experienced febrile grade 2 neutropenia after the second cycle and one 315	  
asymptomatic grade 4 neutropenia after the third cycle; however they both recovered 316	  
with supportive care, and subsequent dose reductions were not considered necessary. 317	  
Notably, none of the dogs developed sepsis due to neutropenia.  318	  
Overall, the incidence of gastrointestinal toxicity (vomiting and loss of appetite) was 319	  
low, and no significant differences were observed between Group 1 and 2. We assume 320	  
that the standard antiemetic medication with maropitant prevented the onset of grade III 321	  
to IV emesis. 322	  
Specific guidelines for dose adjustments of antineoplastic agents are not standardized in 323	  
veterinary oncology; however a 20% to 25% reduction is commonly recommended for 324	  
the subsequent dose in patients experiencing moderate to severe dose-limiting toxicity 325	  
(i.e. grade 3-4 toxicity), such as neutropenia or emesis.32 Excessive toxicity is also more 326	  
likely to increase treatment-associated costs, have chances of losing owners’ 327	  
compliance and, least but not last, to negatively affect patients’ survival. On the other 328	  
hand, the greatest benefit achievable with anticancer cytotoxic therapy requires a 329	  
commitment to dose intensity; lack of or reduced dose density have the potential to be 330	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detrimental in cancer treatment, especially in neoplastic diseases known to have the 331	  
potential of high growth fractions.33,34 Of course, optimal dose intensity demands 332	  
therapeutic monitoring in order to either reduce or increase doses based on the patient’s 333	  
capacity to maintain a high quality of life (QoL) during effective therapy. In the 334	  
mentioned cases, a close monitoring of clinical signs by the clinicians, and detailed 335	  
owners’ information resulted in no lack of compliance. Dogs recovered completely and 336	  
haematological abnormalities resolved without requiring hospitalization and with no 337	  
perception of durable decline in QoL by the owner. We therefore elected not to reduce 338	  
chemotherapy doses at the time of the following cycle, resulting in no effect on the 339	  
intended SDI of the chemotherapy protocol. Such toxicities did not recur during 340	  
treatment, being attributable to transient and undiagnosed comorbidities that might have 341	  
enhanced chemotherapy toxicities, a degree of individual tolerance to chemotherapy, 342	  
adaption of the owner to gastrointestinal signs or a combination of these. Our approach 343	  
was based on the thought that dose reductions should not be solely based on the degree 344	  
of toxicity, but decided on a broader spectrum of variants such as risk of cancer 345	  
progression, presenting clinical signs and owner compliance. Moreover, cumulative 346	  
toxicity was also not observed in our study, in fact haematological abnormalities were 347	  
reversible and the degree of toxicity (either hematological of gastrointestinal) did not 348	  
increase in the following treatment cycles.  349	  
These results differ from a recent publication that reported the use of combined 350	  
chemotherapy protocol consisting of doxorubicin, dacarbazine, and vincristine (DAV).15 351	  
In that study chemotherapy-related side effects were notable, including several high-352	  
grade hematologic and gastrointestinal toxic events. Moreover, almost 20% of the dogs 353	  
had their protocol discontinued due to chemotherapy-related toxicities; however no 354	  
treatment-related deaths occurred.15  355	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This could have multiple explanations. In the current study, the total intended dose of 356	  
dacarbazine was divided in 5 daily boluses, whereas in the DAV study this was 357	  
administered as a single dose over 8h infusion; in fact it has been suggested that daily 358	  
dacarbazine IV boluses may cause reduced gastrointestinal toxicity than slow IV 359	  
infusions, without negatively affecting antitumour activity.16,28 Moreover, vincristine 360	  
was not administered in ADTIC dogs, possibly reducing the risk of gastrointestinal 361	  
toxicity. It should be also noted that the majority of dogs included in Group 2 presented 362	  
with no advanced clinical stage, whereas in the DAV study dogs were most likely to 363	  
have stage III disease; dogs with advanced disease could easily have reduced 364	  
performance status, potentially leading to enhanced susceptibility to chemotherapy 365	  
toxicity.35   366	  
No evidence of clinical cardiotoxicity was noted in our study. This finding could be 367	  
attributed to the entry criteria with regard to cardiac function, the limited number of 368	  
dogs in the study and/or the low number of doxorubicin treatments administered not 369	  
reaching the cumulative dose for cardiotoxicity. 370	  
Despite the small size of this study, our results document an advantage in the use of 371	  
ADTIC over AC for the treatment of biologically aggressive canine HSA in terms of 372	  
metastatic control and survival, particularly for stage II HSA. In Group 1, 83% of dogs 373	  
(AC protocol) where euthanized due to HSA progression with a MST of 142 days, 374	  
whereas in Group 2 (ADTIC protocol) 44.4% of dogs died due to tumour-related causes 375	  
with a MST >550days (p=0.011); moreover in Group 2 the one and one and a half years 376	  
survival was achieved in 66.8% and 55.8% respectively, whereas none of the patient 377	  
reached 1 year survival in Group 2. From our perspective, this data is probably the most 378	  
relevant supporting further the benefit of ADTIC on patients survival, and may also 379	  
suggest that a notable proportion of dogs with biologically aggressive HSA may still 380	  
have a good outcome, if chemotherapy is started in the absence of macroscopic 381	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metastatic disease. However, this data should be interpreted carefully as it may be 382	  
biased by the small number of dogs enrolled in Group 2 and, although debated, to the 383	  
potentially less aggressive biological behavior of renal and subcutaneous HSA 384	  
compared to other visceral locations.36,37 This being said, it must be acknowledged that 385	  
subcutaneous HSA with the longest diameter >6 cm have been significantly associated 386	  
with a shorter time to tumour progression and survival time than smaller tumors.37 In 387	  
the current study, the 3 subcutaneous HSA measured 8, 6.5 and 12 cm, respectively, 388	  
supporting the aggressive behaviour and the increased likelihood of developing 389	  
metastatic disease.  390	  
Concerning TTM, 66.6% of the dogs treated with AC developed distant metastasis 391	  
during the study compared to 44% of the dogs treated with ADTIC. Like survival, TTM 392	  
was significantly longer (p=0.021) if ADTIC was used as adjuvant first-line treatment 393	  
strategy. This finding may be due to several reasons. Although cyclophosphamide and 394	  
dacarbazine are both alkylating agents, their antitumor activity differs considerably due 395	  
to different pharmacokinetic features, lipid solubility, membrane transport properties 396	  
and specific enzymatic reactions capable of repairing alkylation sites on DNA.16,38 397	  
Cyclophosphamide interferes with DNA replication and transcription of RNA, thereby 398	  
resulting in disruption of nucleic acid function.38 Dacarbazine acts by means of 399	  
alkylation, antimetabolite activity as a purine precursor, and interaction with sulfhydryl 400	  
groups in proteins.16 Because the issue of optimizing the treatment strategy to maximize 401	  
efficacy while limiting toxicity has clinical implications, here we further investigated 402	  
dose intensity of both adopted protocols by directly comparing cyclophosphamide and 403	  
dacarbazine. Dacarbazine has greater individual fractional dose intensity when 404	  
compared with cyclophosphamide, ultimately leading to a greater SDI in combination 405	  
with doxorubicin. All dogs included in the study received the scheduled doses without 406	  
17	  
	  
any need for dose reduction, therefore ADTIC treated dogs received a more intense 407	  
chemotherapy, possibly leading to longer TTM and survival. 408	  
Furthermore, beside its cytotoxic activity, dacarbazine has been demonstrated to have in 409	  
mice antimetastatic property, the underlying mechanism being related to its capacity to 410	  
enhance tumor immunogenicity.39,40 In this study, dogs treated with ADTIC had a 411	  
longer TTM, which may either reflect the capacity of dacarbazine to inhibit metastatic 412	  
spread or be due to the small sample size of the study. 413	  
Limitations of this study include lack of randomization, low number of cases and 414	  
different tumour site origin. Although subcutaneous and visceral HSA have been 415	  
described to have an aggressive biological behaviour,1,3,4,37 little is known about 416	  
mesenteric HSA.2 A dog with mesenteric HSA was included in the present study. In 417	  
addition, 2 dogs included in Group 2 received a rescue protocol after having developed 418	  
distant metastases, possibly contributing to increased survival.  419	  
To conclude, the combination ADTIC was well tolerated and may prolong TTM and 420	  
survival time in dogs with biologically aggressive HSA, especially if not metastatic at 421	  
presentation.  422	  
 423	  
 424	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Captions to figures: 559	  
Figure 1: Time to metastases for dogs treated with ADTIC (line) and AC (dots). In the 560	  
ADTIC group, dogs had a longer time to metastases (>550 days versus 112 days; P=0.021). 561	  
 562	  
Figure 2: Survival time for dogs treated with ADTIC (line) and AC (dots). In the 563	  
ADTIC group, dogs had a longer survival time (>550 days versus 142 days; P=0.011). 564	  
 565	  
